Cor Integrilin Higher Dosing Data First Quarter FDA Filing Expected
Executive Summary
Cor Therapeutics expects to file study data with FDA during the first quarter for a change in the Integrilin (eptifibatide) dosing regimen for patients undergoing coronary stent procedures.